ProCE Banner Activity

Optimal Dosing of the Poly(ADP-Ribose) Polymerase Inhibitor Niraparib

Slideset Download
Conference Coverage
Individualized dosing of niraparib based on weight and platelet count improves tolerability with no loss of efficacy.

Released: June 01, 2020

Expiration: May 31, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono